Ot­su­ka sub­sidiary gets date with FDA for Lon­surf com­bo; Vax­cyte sells stock to bankroll PhI­II vac­cine tri­al

Ot­su­ka sub­sidiary Tai­ho On­col­o­gy an­nounced Tues­day morn­ing that the FDA has ac­cept­ed its ap­pli­ca­tion for a com­bo in­di­ca­tion for Lon­surf, which is cur­rent­ly ap­proved for third- or fourth-line metasta­t­ic col­orec­tal can­cer.

With pri­or­i­ty re­view, the FDA has un­til Aug. 13 to de­cide on whether or not to ap­prove Tai­ho’s drug in com­bi­na­tion with Roche’s Avastin in the same lines of treat­ment that Lon­surf is al­ready avail­able as a monother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.